Brexanolone, to be marketed by Sage Therapeutics as Zulresso, was initially approved in March 2019, as a treatment for postpartum depression. At that time, we were told that Zulresso would be available in June 2019. [...]
In our clinic, we see many women with postpartum depression. Some women know that something is wrong fairly soon after the depression sets in, and they seek help; however, far too many women present long [...]
According to recent studies, the participation of fathers in childcare nearly doubled between 1965 and 2011. Despite this growing involvement of fathers in their children’s lives, pediatric visits continue to be focused on the mother-child [...]
Neuroimaging studies over the last few years have demonstrated that exposure to maternal depression can lead to changes in the architecture of the child’s brain, changes which may persist into adulthood and are associated with [...]
Over the last decade, public awareness of the mental health challenges women face has grown tremendously, and we can say with certainty that we have succeeded in putting this important topic firmly on the medical [...]
Since the the Food and Drug Administration (FDA) approved brexanolone as an intravenous infusion for the treatment of postpartum depression last week, we have been deluged with questions from patents, providers and the media regarding [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). Â SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. Â Since that time, Sage Therapeutics [...]
Postpartum depression (PPD) is a common and complicated illness, affecting about 15% of women in the perinatal period. Recent research from the PACT consortium (Postpartum Depression: Action Toward Causes and Treatment) has sought to classify [...]
Women with postpartum depression often complain of social isolation, and multiple studies have documented that having inadequate social supports is a risk factor for postpartum depression.  A recent study suggests that increasing a mother’s social [...]
In 2016, the US Preventive Services Task Force (USPSTF) recommended that all adults, including pregnant and postpartum women, should be screened for depression; the task force has extended those recommendations by stating that all pregnant [...]
